Eric Lefkofsky is Creating the Clinical Study Singularity

Eric Lefkofsky is one of the biggest names in medical philanthropy throughout the United States. Having donated tens of millions of dollars to cancer research alone, the entrepreneur has become one of the most appreciated philanthropists of his age. But unlike many independently wealthy philanthropists, Lefkofsky likes to take a more hands-on approach to his largesse. In 2016, Lefkofsky founded a company, Tempus, which seeks to revolutionize the way in which cancer is treated through putting the most powerful information available into the hands of oncologists.

After a close family member was diagnosed with cancer, Lefkofsky was dismayed to discover that many oncologists working in the field today have less access to vital information than the typical truck driver. This disturbing realization prompted Lefkofsky to begin looking into ways in which better sources of data and analytic intelligence can be put into the hands of treating physicians in real-time. He eventually came to the conclusion that such new technologies as CRISPR and human gene sequencing were not being used to anywhere near their full potential. These new technologies were a potential treasure trove of data that could be used by oncologists in real time to formulate far more effective treatment protocols for each of their patients and learn more about Eric.

Eventually, the idea for Tempus began coalescing in Lefkofsky’s head. It would be a means to effectively allow oncologists to answer the same questions, even with complex data sets, that would have previously only been possible to effectively answer through the use of large-scale clinical studies. Even a decade ago, such a platform would have been impossible to create. But today, through the use of such means as artificial intelligence and the vast computing power contained in the cloud, it is possible to sift through mind-boggling volumes of data, teasing out the subtle patterns and correlations that exist between seemingly unrelated factors and more information click here.

Lefkofsky believes that this new technology will effectively enable physicians to gain a near-infinite granularity in their understanding of how patients react to medicines and treatments. It will eventually allow doctors to custom design treatment protocols to each individual patient.

More Visit: https://www.bizjournals.com/chicago/news/2017/04/12/groupon-co-founder-moves-to-help-youth-access-art.html

Leave a Reply

Your email address will not be published. Required fields are marked *